查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930051

全球幹細胞市場：市場規模、佔有率、成長率、產業分析、按類型、應用和地區劃分的考量、未來預測（2025-2034）

Stem Cells Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 請詢問到貨日

價格

幹細胞市場成長因子

預計2025年全球幹細胞市場規模將達到193.4億美元，並在2026年成長至220.9億美元。在預測期內，預計到2034年，市場規模將達到799.5億美元，2026年至2034年的複合年增長率（CAGR）為17.45%。北美地區在2025年將以53.10%的市佔率領先，這主要得益於活躍的研發活動、幹細胞療法的高普及率、監管支持以及不斷增加的臨床試驗活動。

幹細胞具有分化成各種特殊細胞的能力，廣泛應用於再生醫學和治療藥物的研發。慢性疾病的增加以及對新型療法日益增長的需求，正推動全球範圍內對研究項目、臨床試驗和產品開發的大量投資。

市場驅動因素

幹細胞市場的成長主要得益於其在研究和治療領域應用範圍的不斷擴大。幹細胞正越來越多地應用於再生醫學、疾病建模、藥物研發和臨床應用。利用人類多能幹細胞進行的臨床試驗數量穩定成長，其中大部分研究由美國、中國、日本和英國進行。

政府主導的各項措施和資助計畫也進一步加速了市場成長。例如，2023年5月，馬裡蘭州幹細胞研究委員會撥款超過1,410萬美元，用於促進幹細胞技術的創新研究。此外，市場參與者之間的聯盟和收購，例如Bio-Techne於2022年7月收購Namocell，正在增強研發能力並拓展產品線。

市場限制因子

儘管潛力巨大，但該市場仍面臨著與倫理問題和監管複雜性相關的挑戰。特別是就人類胚胎幹細胞（ES細胞）而言，圍繞胚胎破壞、安全問題以及未經FDA批准的臍帶血衍生產品的風險等倫理爭議，可能會阻礙其在某些地區的應用和研究。

市場趨勢

一個主要趨勢是誘導多能幹細胞（iPS細胞）的出現，它可作為ES細胞的替代品。 iPS細胞由成體體細胞重編程而來，獲得多能性，從而消除了倫理問題，使其成為疾病建模、藥物研發和再生醫學的理想選擇。富士膠片細胞動力學公司和其他公司已推出iPS細胞衍生試劑盒，以推進中樞神經系統（CNS）藥物的研究。

另一個趨勢是注重合作和協同研究。例如，Pluristyx 於 2023 年 7 月與 Stem Genomics 合作，評估多能幹細胞系的基因組穩定性。 Cordlife Hong Kong Limited 也正與 Hong Kong Regen MedTech 合作，以增強基於間質幹細胞 (MSC) 的療法。

依細分市場分析

依細胞類型：市場細分為間質幹細胞 (MSC)、胚胎幹細胞 (ESC)、成體幹細胞 (ASC) 和誘導多能幹細胞 (iPS 細胞)。由於再生醫學和研究應用的高需求，MSC 在 2024 年佔最大佔有率。然而，由於其倫理優勢和多樣化的應用潛力，預計 iPS 細胞將實現最高的複合年增長率。

依應用：市場細分為研發及臨床應用。 2024年，研發領域佔主導地位，這主要得益於幹細胞在疾病模型建構和類器官開發中的應用日益廣泛。在神經系統疾病、心臟病和罕見疾病再生醫學的推動下，臨床應用預計將在預測期內呈現最高的成長率。

按最終用戶劃分：2024年，製藥和生物技術公司佔最大佔有率，這主要得益於大規模臨床研究和基於誘導多能幹細胞（iPS細胞）的研究的普及。由於合作研究的增加和政府資助的增加，學術和研究機構預計將以最高的複合年增長率成長。

區域展望

北美市場佔主導地位，預計2025年市場規模將達到102.7億美元，這得益於其強大的臨床試驗、完善的研究基礎設施和完善的監管審批體系。預計歐洲市場將保持穩定成長，其中德國和英國在罕見疾病治療領域的研發投資處於領先地位。亞太地區預計將呈現最高的複合年增長率，這主要得益於臨床試驗的增加、專業人才的湧現以及政府對幹細胞研究的投入。預計到2026年，日本市場規模將達到11億美元，中國將達到18.6億美元，印度將達到6.1億美元。拉丁美洲以及中東和非洲的市場佔有率較低，主要是由於應用範圍和基礎設施有限。

報告範圍

本報告對全球幹細胞市場進行了全面分析，重點關注市場規模、成長趨勢、細胞類型、應用、終端用戶、區域分析、競爭格局、市場驅動因素、限制因素和新興趨勢。報告涵蓋了近期市場驅動因素，並為利害關係人提供策略洞察，以掌握成長機會。

市場擴張的驅動因素包括幹細胞在再生醫學、疾病建模和治療開發等領域的廣泛應用，以及投資增加、政府資助和產業參與者之間的合作。誘導多能幹細胞（iPS細胞）作為胚胎幹細胞的符合倫理的替代方案，其興起正進一步加速市場接受度，並支持慢性病、罕見疾病和神經系統疾病的研發和臨床應用。

儘管倫理問題、監管挑戰和安全問題仍然需要考慮，但臨床試驗的持續增加、創新產品的推出以及產學研合作的日益密切，都凸顯了該市場的韌性和長期潛力。總體而言，幹細胞市場預計將持續擴張，為利害關係人提供機會，以掌握全球對先進療法和研究解決方案日益增長的需求。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 幹細胞研究資助計畫概述
  • 主要國家和地區相關慢性疾病的盛行率/發生率
  • 主要公司新產品發布
  • 主要公司研發管線分析
  • 幹細胞市場主要新創企業概覽
  • 主要產業趨勢：併購合作關係
  • 新冠疫情對市場的影響

第五章：全球幹細胞市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依細胞類型劃分
    • 胚胎幹細胞 (ESCs)
    • 間質幹細胞 (MSCs)
    • 成體幹細胞
    • 誘導性多能幹細胞 (iPSCs)
  • 市場分析、洞察與預測：依應用領域劃分
    • 研究
    • 臨床
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院
    • 製藥和生技公司
    • 學術和研究機構機構
    • 其他
  • 市場分析、洞察與預測：按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美幹細胞市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲幹細胞市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國王國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區幹細胞市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲幹細胞市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

章節10：中東與非洲幹細胞市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • PromoCell GmbH
    • AcceGen
    • Bio-Techne
    • Cellular Engineering Technologies
    • Merck KgaA
    • Thermo Fisher Scientific Inc.
    • Lonza
    • Miltenyi Biotec B.V. &Co. KG
    • STEMCELL Technologies
Product Code: FBI105138

Growth Factors of stem cells Market

The global stem cells market was valued at USD 19.34 billion in 2025 and is projected to grow to USD 22.09 billion in 2026. Over the forecast period, the market is expected to reach USD 79.95 billion by 2034, exhibiting a CAGR of 17.45% from 2026 to 2034. North America led the market in 2025 with a 53.10% share, driven by strong research and development activities, high adoption of stem cell therapies, regulatory support, and increasing clinical trial activity.

Stem cells, with their ability to differentiate into specialized cells, are widely applied in regenerative medicine and therapeutic development. The rise in chronic diseases and demand for novel therapies have fueled significant investment in research initiatives, clinical trials, and product development globally.

Market Drivers

The growth of the stem cells market is primarily driven by the expansion of applications in research and therapeutics. Stem cells are increasingly utilized in regenerative medicine, disease modeling, drug discovery, and clinical applications. Clinical trials involving human pluripotent stem cells have increased steadily, with the U.S., China, Japan, and the U.K. conducting the majority of such studies.

Government-backed initiatives and funding programs further accelerate market growth. For example, the Maryland Stem Cell Research Commission allocated over USD 14.1 million in May 2023 to promote innovative research in stem cell technologies. Collaborations and acquisitions among market players, such as Bio-Techne acquiring Namocell in July 2022, enhance R&D capabilities and expand the product pipeline.

Market Restraints

Despite its potential, the market faces challenges related to ethical concerns and regulatory complexities, especially with human embryonic stem cells (ESCs). Ethical debates surrounding embryo destruction, safety concerns, and the risk of non-FDA-approved umbilical cord-derived products can hamper adoption and research in certain regions.

Market Trends

One key trend is the emergence of induced pluripotent stem cells (iPSCs) as an alternative to ESCs. iPSCs eliminate ethical concerns by reprogramming adult somatic cells to obtain pluripotency, making them ideal for disease modeling, drug discovery, and regenerative therapies. Companies such as FUJIFILM Cellular Dynamics have launched iPSC-derived kits to advance CNS drug research.

Another trend is the focus on partnerships and collaborations. For instance, Pluristyx, Inc. partnered with Stem Genomics in July 2023 to evaluate the genomic stability of pluripotent stem cell lines, and Cordlife Hong Kong Limited collaborated with Hong Kong Regen MedTech to enhance MSC-based therapies.

Segmentation Analysis

By Cell Type: The market is categorized into Mesenchymal Stem Cells (MSCs), Embryonic Stem Cells (ESCs), Adult Stem Cells (ASCs), and iPSCs. MSCs held the largest share in 2024 due to their high demand in regenerative medicine and research applications, while iPSCs are projected to register the fastest CAGR owing to their ethical advantages and diverse applications.

By Application: The market is segmented into research and clinical applications. The research segment dominated in 2024, driven by increasing use of stem cells in disease modeling and organoid development. The clinical segment is expected to record the fastest growth over the forecast period, supported by regenerative therapies for neurological disorders, cardiac diseases, and rare conditions.

By End-user: Pharmaceutical and biotechnology companies accounted for the largest share in 2024 due to extensive clinical studies and adoption of iPSC-based research. Academic and research institutes are expected to grow at the highest CAGR as collaborative research and government funding increase.

Regional Insights

North America dominated the market with USD 10.27 billion in 2025, supported by robust clinical trials, research infrastructure, and regulatory approvals. Europe is projected to grow steadily, with Germany and the U.K. leading R&D investments in rare disease therapies. Asia Pacific is expected to exhibit the highest CAGR, driven by increasing clinical trials, skilled professionals, and government investments in stem cell research. Japan is projected to reach USD 1.10 billion by 2026, China USD 1.86 billion, and India USD 0.61 billion. Latin America and the Middle East & Africa accounted for lower shares due to limited adoption and infrastructure.

Competitive Landscape

The market is highly competitive, with leading companies focusing on R&D, acquisitions, collaborations, and new product launches. Key players include Thermo Fisher Scientific, Merck KGaA, STEMCELL Technologies, Miltenyi Biotec, Bio-Techne, AcceGen, Lonza, PromoCell GmbH, and MEDIPOST Co. Strategic partnerships, such as Thermo Fisher's collaboration with UCSF for cell therapy production in March 2023, strengthen technological capabilities and market presence.

Key Industry Developments

  • December 2023: GenCure partnered with the University of Texas at San Antonio for cellular therapy development.
  • August 2023: BlueRock Therapeutics and bit.bio signed an agreement for iPSC-derived Treg therapies.
  • July 2023: PromoCell GmbH launched PromoExQ MSC Growth Medium XF for hMSC expansion.
  • June 2023: FUJIFILM Cellular Dynamics launched its iPSC-derived Blood-Brain Barrier Isogenic Kit.

Report Coverage

The report provides a comprehensive analysis of the global stem cells market, focusing on market size, growth trends, cell types, applications, end-users, regional analysis, competitive landscape, market drivers, restraints, and emerging trends. It encompasses factors driving the market over recent years and offers strategic insights for stakeholders to capitalize on growth opportunities.

Conclusion

The global stem cells market, valued at USD 19.34 billion in 2025, is poised for significant growth, reaching USD 22.09 billion in 2026 and projected to attain USD 79.95 billion by 2034, reflecting a robust CAGR of 17.45% during 2026-2034. North America maintained its leading position in 2025, driven by strong R&D investments, high adoption of stem cell therapies, and regulatory support, while Asia Pacific is expected to emerge as the fastest-growing region due to increasing clinical trials, skilled professionals, and government initiatives.

Market expansion is fueled by the growing applications of stem cells in regenerative medicine, disease modeling, and therapeutic development, coupled with rising investments, government funding, and collaborations among industry players. The rise of iPSCs as an ethical alternative to embryonic stem cells has further accelerated market adoption, supporting research and clinical applications across chronic, rare, and neurological diseases.

While ethical concerns, regulatory challenges, and safety issues remain considerations, the continuous growth in clinical trials, innovative product launches, and academic-industry partnerships underscores the market's resilience and long-term potential. Overall, the stem cells market is positioned for sustained expansion, with opportunities for stakeholders to capitalize on the increasing demand for advanced therapies and research solutions globally.

Segmentation By Cell Type

  • Embryonic Stem Cells (ESCs)
  • Mesenchymal Stem Cells (MSCs)
  • Adult Stem Cells
  • Induced Pluripotent Stem Cells (iPSCs)

By Application

  • Research
  • Clinical

By End-user

  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others

By Region

  • North America (By Cell Type, Application, End-user, Country/Sub-Region)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Cell Type, Application, End-user, Country/Sub-Region)
    • U.K. (By Application)
    • Germany (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Scandinavia (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Cell Type, Application, End-user, Country/Sub-Region)
    • Japan (By Application)
    • China (By Application)
    • India (By Application)
    • Australia (By Application)
    • South Korea (By Application)
    • Southeast Asia (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Cell Type, Application, End-user, Country/Sub-Region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Rest of Latin America (By Application)
  • The Middle East & Africa (By Cell Type, Application, End-user, Country/Sub-Region)
    • South Africa (By Application)
    • GCC (By Application)
    • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Funding Initiatives for Stem Cell Research
  • 4.2. Prevalence/Incidence of Relevant Chronic Disorders - By Key Countries/Region
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Snapshot of Key Start-ups in the Stem Cells Market
  • 4.6. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.7. Impact of COVID-19 on the Market

5. Global Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Cell Type
    • 5.1.1. Embryonic Stem Cells (ESCs)
    • 5.1.2. Mesenchymal Stem Cells (MSCs)
    • 5.1.3. Adult Stem Cells
    • 5.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Research
    • 5.2.2. Clinical
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals
    • 5.3.2. Pharmaceutical and Biotechnology Companies
    • 5.3.3. Academic & Research Institutes
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Cell Type
    • 6.1.1. Embryonic Stem Cells (ESCs)
    • 6.1.2. Mesenchymal Stem Cells (MSCs)
    • 6.1.3. Adult Stem Cells
    • 6.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Research
    • 6.2.2. Clinical
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals
    • 6.3.2. Pharmaceutical and Biotechnology Companies
    • 6.3.3. Academic & Research Institutes
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Application
    • 6.4.2. Canada
      • 6.4.2.1. By Application

7. Europe Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Cell Type
    • 7.1.1. Embryonic Stem Cells (ESCs)
    • 7.1.2. Mesenchymal Stem Cells (MSCs)
    • 7.1.3. Adult Stem Cells
    • 7.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Research
    • 7.2.2. Clinical
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals
    • 7.3.2. Pharmaceutical and Biotechnology Companies
    • 7.3.3. Academic & Research Institutes
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
      • 7.4.1.1. By Application
    • 7.4.2. Germany
      • 7.4.2.1. By Application
    • 7.4.3. France
      • 7.4.3.1. By Application
    • 7.4.4. Spain
      • 7.4.4.1. By Application
    • 7.4.5. Italy
      • 7.4.5.1. By Application
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Application
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Application

8. Asia Pacific Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Cell Type
    • 8.1.1. Embryonic Stem Cells (ESCs)
    • 8.1.2. Mesenchymal Stem Cells (MSCs)
    • 8.1.3. Adult Stem Cells
    • 8.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Research
    • 8.2.2. Clinical
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals
    • 8.3.2. Pharmaceutical and Biotechnology Companies
    • 8.3.3. Academic & Research Institutes
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Application
    • 8.4.2. China
      • 8.4.2.1. By Application
    • 8.4.3. India
      • 8.4.3.1. By Application
    • 8.4.4. Australia
      • 8.4.4.1. By Application
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Application
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Application

9. Latin America Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Cell Type
    • 9.1.1. Embryonic Stem Cells (ESCs)
    • 9.1.2. Mesenchymal Stem Cells (MSCs)
    • 9.1.3. Adult Stem Cells
    • 9.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Research
    • 9.2.2. Clinical
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals
    • 9.3.2. Pharmaceutical and Biotechnology Companies
    • 9.3.3. Academic & Research Institutes
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Application
    • 9.4.2. Mexico
      • 9.4.2.1. By Application
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Application

10. Middle East & Africa Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Cell Type
    • 10.1.1. Embryonic Stem Cells (ESCs)
    • 10.1.2. Mesenchymal Stem Cells (MSCs)
    • 10.1.3. Adult Stem Cells
    • 10.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Research
    • 10.2.2. Clinical
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Hospitals
    • 10.3.2. Pharmaceutical and Biotechnology Companies
    • 10.3.3. Academic & Research Institutes
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Application
    • 10.4.2. South Africa
      • 10.4.2.1. By Application
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Application

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. PromoCell GmbH
      • 11.2.1.1. Overview
      • 11.2.1.2. Cell Type
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. AcceGen
      • 11.2.2.1. Overview
      • 11.2.2.2. Cell Type
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bio-Techne
      • 11.2.3.1. Overview
      • 11.2.3.2. Cell Type
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Cellular Engineering Technologies
      • 11.2.4.1. Overview
      • 11.2.4.2. Cell Type
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Merck KgaA
      • 11.2.5.1. Overview
      • 11.2.5.2. Cell Type
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Thermo Fisher Scientific Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Cell Type
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Lonza
      • 11.2.7.1. Overview
      • 11.2.7.2. Cell Type
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Miltenyi Biotec B.V. & Co. KG
      • 11.2.8.1. Overview
      • 11.2.8.2. Cell Type
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. STEMCELL Technologies
      • 11.2.9.1. Overview
      • 11.2.9.2. Cell Type
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 2: Global Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 3: Global Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 4: Global Stem Cells Market Revenue (USD billion) Forecast, by Region,2021-2032
  • Table 5: North America Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 6: North America Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 7: North America Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 8: North America Stem Cells Market Revenue (USD billion) Forecast, By Country,2021-2032
  • Table 9: U.S. Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 10: Canada Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 11: Europe Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 12: Europe Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 13: Europe Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 14: Europe Stem Cells Market Revenue (USD billion) Forecast, By Country/ Sub-region,2021-2032
  • Table 15: Germany Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 16: U.K. Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 17: France Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 18: Italy Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 19: Spain Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 20: Scandinavia Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 21: Rest of Europe Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 22: Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 23: Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 24: Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 25: Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, By Country/ Sub-region,2021-2032
  • Table 26: India Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 27: China Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 28: Japan Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 29: South Korea Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 30: Australia Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 31: Rest of Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 32: Latin America Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032

Table 33: Latin America Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032

  • Table 34: Latin America Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 35: Latin America Stem Cells Market Revenue (USD billion) Forecast, By Country/ Sub-region,2021-2032
  • Table 36: Brazil Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 37: Mexico Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 38: Rest of Latin America Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 39: Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 40: Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 41: Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 42: Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, By Country/ Sub-region,2021-2032
  • Table 43: GCC Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 44: South Africa Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 45: Rest of Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032

List of Figures

  • Figure 1: Global Stem Cells Market Revenue Breakdown (USD billion, %) by Region,2025 &2034
  • Figure 2: Global Stem Cells Market Value Share (%), by Cell Type,2025 &2034
  • Figure 3: Global Stem Cells Market Value Share (%), by Application,2025 &2034
  • Figure 4: Global Stem Cells Market Value Share (%), by End-user,2025 &2034
  • Figure 5: Global Stem Cells Market Value (USD billion), by Region,2025 &2034
  • Figure 6: North America Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 7: North America Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 8: North America Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 9: North America Stem Cells Market Value Share (%), by Application,2025
  • Figure 10: North America Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 11: North America Stem Cells Market Value Share (%), by End-user,2025
  • Figure 12: North America Stem Cells Market Value (USD billion), By Country/Sub-region,2025 &2034
  • Figure 13: North America Stem Cells Market Value Share (%), By Country/Sub-region,2025
  • Figure 14: Europe Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 15: Europe Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 16: Europe Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 17: Europe Stem Cells Market Value Share (%), by Application,2025
  • Figure 18: Europe Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 19: Europe Stem Cells Market Value Share (%), by End-user,2025
  • Figure 20: Europe Stem Cells Market Value (USD billion), By Country/ Sub-region,2025 &2034
  • Figure 21: Europe Stem Cells Market Value Share (%), By Country/ Sub-region,2025
  • Figure 22: Asia Pacific Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 23: Asia Pacific Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 24: Asia Pacific Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 25: Asia Pacific Stem Cells Market Value Share (%), by Application,2025
  • Figure 26: Asia Pacific Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 27: Asia Pacific Stem Cells Market Value Share (%), by End-user,2025
  • Figure 28: Asia Pacific Stem Cells Market Value (USD billion), By Country/ Sub-region,2025 &2034
  • Figure 29: Asia Pacific Stem Cells Market Value Share (%), By Country/ Sub-region,2025
  • Figure 30: Latin America Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 31: Latin America Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 32: Latin America Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 33: Latin America Stem Cells Market Value Share (%), by Application,2025
  • Figure 34: Latin America Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 35: Latin America Stem Cells Market Value Share (%), by End-user,2025
  • Figure 36: Latin America Stem Cells Market Value (USD billion), By Country/ Sub-region,2025 &2034
  • Figure 37: Latin America Stem Cells Market Value Share (%), By Country/ Sub-region,2025
  • Figure 38: Middle East & Africa Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 39: Middle East & Africa Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 40: Middle East & Africa Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 41: Middle East & Africa Stem Cells Market Value Share (%), by Application,2025
  • Figure 42: Middle East & Africa Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 43: Middle East & Africa Stem Cells Market Value Share (%), by End-user,2025
  • Figure 44: Middle East & Africa Stem Cells Market Value (USD billion), By Country/ Sub-region,2025 &2034
  • Figure 45: Middle East & Africa Stem Cells Market Value Share (%), By Country/ Sub-region,2025
  • Figure 46: Global Stem Cells Market Share (%), By Company,2025